CQUEST

Are you a member of the community involved in the support and care of people with cancer? Nominations are now open for the 2026 #JeannieFerrisAward - recognising outstanding contributions in improving cancer outcomes. Visit bit.ly/414KbNP

Tarlatamab is changing the game in SCLC. See the trial data, understand the PBS landscape, and master the clinical use. Secure your place at our Small Cell Lung Cancer Masterclass now 👉 🚨 Limited spots available. 📅 Date: March 20 ⏰ Time: 10:00AM - 4:30PM

Only one week remains to volunteer on the ISOQOL Awards Subcommittee or a Travel Scholarship Selection Panel! Submit your application by 16 March to get involved and help shape recognition in the HRQL field. Learn more: buff.ly/p5DnQZt

It's just one week until we kick off one of the biggest events of the year in the Australian & NZ RO calendar -- our ASM in Melbourne. Register to join us for a fabulous program covering the latest research & technology, and the future of clinical trials. ap1.hubs.ly/y0D7DL0

🔬 STRIVE clinical trial now open in Aotearoa, New Zealand ANZGOG, in partnership with @CDNCancerTrials (CCTG), is pleased to announce the activation of the STRIVE clinical trial in Aotearoa, New Zealand 🇳🇿 STRIVE (ANZGOG2109/2021; CCTG VU.2) represents an important step forward in advancing evidence-based surgical management for women diagnosed with vulvar squamous cell carcinoma (VSCC). VSCC accounts for more than 90% of vulvar cancers and arises via two distinct biological pathways: • HPV-associated • HPV-independent, often linked to lichen sclerosus Emerging evidence suggests these subtypes behave differently, with implications for surgical management and recurrence risk. However, optimal treatment strategies have not been formally tested in a prospective trial. STRIVE is an international, prospective stratification study designed to refine surgical decision-making based on tumour biology, including HPV status and molecular markers such as p53 and dVIN. The trial aims to: • Improve risk stratification • Inform margin assessment • Reduce recurrence rates • Support personalised treatment pathways For HPV-associated tumours, the study will assess whether less extensive surgery can safely reduce complications and improve function without increasing recurrence risk. For HPV-independent tumours, STRIVE will evaluate whether tailored surgical approaches can reduce the likelihood of recurrence where high-risk biological features are present. The first Australasian site at Auckland City Hospital opened on 30 January 2026 and is actively recruiting, with Dr Lois Eva as Principal Investigator. The study is co-chaired in ANZ by Professor Paul Cohen and Dr Lois Eva. Given the relative rarity of vulvar cancer, international collaboration is essential. STRIVE brings together global expertise to generate the evidence needed to strengthen clinical guidelines and improve outcomes for women. 🔗 ClinicalTrials.gov: NCT06358469 More information: anzgog.org.au/strive-trial #ClinicalTrials #GynaecologicalCancer #VulvarCancer #CancerResearch #GlobalCollaboration

The consumer voice is vital for cancer clinical trials. Bring your lived experience to the table and help shape the future of consumer learning at our CQUEST Co‑Design Workshop. 👉For more info & to register: bit.ly/3MPXEoZ

CQUEST is bringing experts and insights together for this lunchtime seminar. Come along and learn about the core outcome set developed through the Movember Pan Cancer Initiative! 👉 Register here: bit.ly/3OGkLTz FREE for all CTG members!

ASM news incoming.... The theme for the 2026 TOGA ASM is Shaping Tomorrow’s Thoracic Cancer Care Together. We can't wait to see you there. 📅 Save the date: 15-17 July 2026 📍 Location: Pullman Melbourne Albert Park Find out more >buff.ly/4iRWqVO

Have questions about the financial impact of breast cancer? Join us for our free online Q&A on Wed, 18 March from 5-6:30 pm (AEDT) on the topic 'The Financial Impact of Breast Cancer', moderated by Author and Journalist, Annabel Crabb. Register here: bit.ly/49UheJc

Don't miss out on benefits! Renew your ISOQOL membership for 2026 by 31 January. Learn more at isoqol.org/membership/.

🚨 Don’t miss out on early bird savings! The Small Cell Lung Cancer Masterclass is an opportunity to deepen your understanding of this rapidly evolving disease and apply new evidence with confidence. ⏳ Early bird pricing closes 16 February 📅 Date: March 20

🚨 Last chance to register and access the #ISOQOL 2025 virtual conference! Access to the on-demand content, including the plenary recordings and virtual poster hall, will close Thursday, 22 January. Register at buff.ly/yWGIePv.

How can we drive smarter, AI-enabled & efficient clinical trial designs that deliver real-world outcomes? Don't miss the Precision & Performance session at TROG's ASM in Melbourne in March: Speakers include Prof Peter Gibbs & Dr Yu Yang Soon. Register now: ap1.hubs.ly/y0wMJP0

Finishing treatment doesn’t always mean the end of the breast cancer journey. 💗 A/Prof Ben Smith explores fear of recurrence, why it happens, how it affects survivors, and how support and mindfulness can help. Read more: 🔗 bit.ly/4nM8U1R

🌟 TOP 5 REASONS TO ATTEND ANZGOG 2026 As we head toward the EOY, now is the perfect time to reserve your place at ANZGOG’s #ASM2026. 🎥 Hear from ANZGOG Chair Prof. Clare Scott AM 🔗 Find out more & register anzgogasm.org.au Also, LAST CHANCE to SUBMIT YOUR ABSTRACT SUBMISSION, by Monday 8 Dec 2025

Triple-negative breast cancer is one of the hardest types to treat, but new research is offering hope. 💗 4CAST is testing a targeted therapy for AR-positive metastatic TNBC, showing promise in slowing tumour growth and improving response to treatment. bit.ly/4nLBbWp

We're excited to be kicking off TROG's Concept Development Workshop this morning, where we'll discuss how to progress 11 fantastic research ideas put forward by our members. Thanks to sponsor @VarianMedSys for supporting this important initiative & to all contributing to the day.

Blood cancers affect 19,000+ Australians yearly. ALLG is the only not-for-profit blood cancer clinical trials group in ANZ, driving access to new innovative treatments. Through local & global partnerships, we deliver new therapies to patients - allg.org.au.

🔬 OLIO is testing new treatment options for young women with HR+/HER2- breast cancer, the most common type which is often more aggressive in premenopausal women. It’s exploring if olaparib plus chemotherapy before surgery can improve outcomes. breastcancertrials.org.au/trials/olio/

💬 Does your health shape how you value social care? In this study, Jiang et al. found: - Poor mental health: no significant effect on ASCOT valuations - Poor physical health: small, significant shifts in “control”, “safety” & “accommodation” 📚 bit.ly/4gVmsX8